Andrei A. Bunaciu, graduated the Politehnica University of Bucharest in 1979. He received the Ph.D. degree from the Politehnica University of Bucharest, Faculty of Chemistry, Department of Analytical Chemistry in the field of ion-selective membrane electrodes applied in pharmaceutical analysis in 1990. After several years as Senior Researcher in the Institute of Chemical and Pharmaceutical Research and Romanian Intelligence Service, he was also Senior Researcher in Vibrational Spectroscopy Department at SCIENT - Research Center for Instrumental Analysis, Bucharest. Now he is the C.E.O. of AAB_IR research company, www.aab-ir.ro. His research interests concern molecular recognition of pharmaceutical and biological compounds, using infrared spectroscopy techniques. He is the author/co-author of about 92 publications in medical and pharmaceutical analysis, using different analytical techniques. He is the author/co-author of a book VIBRATIONAL SPECTROSCOPY APPLICATIONS IN BIOMEDICAL, PHARMACEUTICAL AND FOOD SCIENCES, A.A. Bunaciu, H.Y. Aboul-Enein and V.D. Hoang, published in 2020 by Elsevier, Inc. and two chapters: VIBRATIONAL SPECTROSCOPY APPLICATIONS IN DRUG-ANALYSIS, A.A. Bunaciu, H.Y. Aboul-Enein, in Encyclopedia of Spectroscopy and Spectrometry, 3rd Edition, Lindon, J.C., Tranter, G.E. and Koppenaal, D.W. (eds.), Oxford; Elsevier, 2017, vol. 4, pp. 575-581, and respectively RECENT APPLICATIONS OF INFRARED SPECTROSCOPY IN BIOMEDICAL ANALYSIS, A.A. Bunaciu, H.Y. Aboul-Enein, in FTIR Spectroscopy: Advances in Research and Applications, edited by Adriana S. Franca and Leandro S. Oliveira, Nova Publishers, NY, USA, 2022, pp. 575-581.

Dr. Octavian Bucur, MD, PhD, is an Associate Investigator at the Viron Molecular Medicine Institute in Boston, MA, USA and Editor in Chief of the journal Discoveries. He has over a decade of training and research experience at the Harvard Medical School: Postdoctoral Fellow at BIDMC and Harvard Medical School, Instructor in Pathology (Faculty), Harvard Medical School (2017-2018); Associate Member, Wyss Institute of Biologically Inspired Engineering at Harvard (2014-2015), Associate Member of the Ludwig Cancer Center at Harvard University, Boston, MA (2016-2018), affiliated with Broad Institute of MIT and Harvard, Boston, MA (2016-2018). Dr. Octavian Bucur has made impactful contributions in several research fields, being one of the main developers of Expansion Pathology (Nature Biotechnology 2017 (in the top 5% of all research outputs scored by Altmetric), Nature Protocols 2020; 3 patents). This method extends the current resolution limit (250 nm) of the optical microscopes to 70 nm, enabling visualization of smaller nanoscopic structures with inexpensive optical microscopy in preserved tissue specimens, after physical tissue expansion. Expansion-related technologies have tremendous implications in several biomedical fields, including diagnostic pathology, neuroscience and molecular medicine. Among the honors and awards received over the years are: Recognition of Outstanding Achievement in Translational and Basic Science Research from the Harvard Medical School Pathology Department; ranked 1st out of >100 - Best Scientific Poster Award (2017, Harvard Medical School Pathology Retreat of MGH, BIDMC, BWH, DFCI, Children’s Hospital Boston); The American Association for Cancer Research (AACR)-Millennium Pharmaceuticals Award (2015, Philadelphia, PA), IUBMB Travel Fellowship (2010, Melbourne, Australia), The American Association for Cancer Research (AACR)-Aflac Award (2008, San Diego, CA); Lady Tata Memorial Trust International Award for Leukemia Research (2007, London, UK); European Union - Leonardo da Vinci Research Award (2004, Magdeburg, Germany); Invited Keynote Speaker/Special Lectures (conferences in San Francisco, Chicago, London (UK), Bucharest (Romania), BIDMC, Harvard Medical School - Boston, Wayne State University - Detroit, Carol Davila University, Romania); Chair of the Scientific Selection Committee for the RALI's Grand Rounds competition, Research Assistant Learning Initiative, Boston (2017-2018); Invited Judge for many undergraduate/graduate research competitions; International grant evaluator. Dr. Octavian Bucur is a Co-Founder, major stakeholder and was the first CEO of Viron Therapeutics, Boston, MA. He is also leading a prolific research group at the Victor Babes National Institute of Pathology in Bucharest, selecting and training some of the most promising students and young researchers from Romania (nextgenpathology.eu).

Dr. Frank Gupton is a professor at virginia commonwealth university and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He is the Floyd D. Gottwald Chair of Pharmaceutical Engineering and also serves as Department Chair of the Chemical and Life Science Engineering Department. His thirty-year industrial career centered on the development and commercialization of chemical processes for pharmaceutical applications. Dr. Gupton’s research group is currently focused on the development of continuous processing technology to facilitate the discovery, development and commercialization of drug products. Prior to joining the faculty at Virginia Commonwealth University, Dr. Gupton served as the Executive Director of North American Process Development for Boehringer Ingelheim Pharmaceuticals and led the commercialization of the widely prescribed HIV drug nevirapine. Dr. Gupton received his Bachelors of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University.

Prof. Yaron Ilan, M.D. serves as the Chief Medical Officer at Immuron Limited. Prof. Ilan is a Partner at Jerusalem Technology Investments Ltd. Prof. Ilan serves as a Medical Director of Exalenz Bioscience Ltd. Dr. Ilan has founded several startup companies and serves as Medical Director and Advisor for several biotech companies. Prof. Ilan served as a Medical Director and Consultant at Immuron Limited. He served as Chief Scientist at Exalenz Bioscience Ltd. Prof. Ilan served as the President at the Israel Liver Association from 2005 to 2008. Prof. Ilan serves as a Director of the Department of Medicine at Hebrew University- Hadassah Medical Center. Prof. Ilan serves as a Director of Exalenz Bioscience Ltd. He served as a Member of Scientific Advisory Board at Therapix Biosciences Ltd. until January 6, 2016. Prof. Ilan served as a Director of Exalenz Bioscience Ltd from May 2006 to April 2015. He was Vice Dean at the Hebrew University Medical School. Prof. Ilan is a world-renowned Scientist in the field of internal medicine, immunology and liver diseases. He holds over 40 patents and has authored more than 250 articles. Dr. Ilan is the Inventor of a number of drugs being developed by international pharmaceutical companies. His post-graduate training was acquired at Albert Einstein College of Medicine, Mount Sinai Medical Center and Harvard University. He graduated as well as studied his Doctorate from Hebrew University of Jerusalem.

Dr Cho’s main research interests have been focusing on cancer studies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. As a seasoned researcher, Dr Cho hasconducted cancer research in using molecular biology, proteomics, genomics, immunology as well as bioinformatics, his current H-index is 67. Dr Cho has published over 500 peer-reviewed papers (Lancet Oncology, Annals of Oncology, Lancet Gastroenterology & Hepatology, Advanced Science, Nature Communications,PNAS,Molecular Cancer,Journal of Thoracic Oncology,Journal of the National Cancer Institute,Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Theranostics, etc) covering cancer biomarkers, proteomics, non-coding RNAs, Chinese medicine and dozens of books including "An Omics Perspective on Cancer Research", "MicroRNAs in Cancer Translational Research", “Drug Repurposing in Cancer Therapy: Approaches and Applications”and "Supportive Cancer Care with Chinese Medicine" etc. The accumulated impact factors of the journals over 3,000 and these papers have received >20,000 citations.

update soon.

Vakhtang Barbakadze has his expertise in isolation and structure elucidation of a new series of plant polyethers, which are endowed with pharmacological properties as immunomodulatory, antioxidant, antiinflammatory, wound-healing and anti-cancer agents. Besides, he interested in enantioselective synthesis and biological activities of basic monomeric moiety of these biopolyethers, synthesis of enantiomerically pure epoxides as chiral building blocks for the production of synthetic analogues of natural polyethers by chemical and enzymetic catalysis. He has received PhD degree in Chemistry and DSci degree in Biology in 1978 and 1999 from Institute of Organic Chemistry, Moscow, Russia and Institute of Biochemistry and Biotechnology, Tbilisi, Georgia, respectively. He is Head of the Department of Plant Biopolymers and Chemical Modification of Natural Compounds at Tbilisi State Medical University I.Kutateladze Institute of Pharmacochemistry. In 1996 and 2002 he has been a visiting scientist at Utrecht University, Departments of Pharmacognosy and Medicinal Chemistry, Utrecht, The Netherlands, by University Scholarship and The Netherlands organization for scientific research (NWO) Scholarship Scientific Program, respectively. He is also an organizing committee member and renowned speaker for many reputed scientific conferences. He has published more than 100 papers in reputed journals. In 2004 he was Georgian State Prize Winner in Science and Technology. 1 Patent P 2012 5391 B (Patents for inventions, NATIONAL INTELLECTUAL PROPERTY CENTER OF GEORGIA SAKPA¬TEN¬TI).

Prof. Shlomo Yitzchaik received his Ph.D. in chemistry from the Weizmann Institute of Science, Israel, in 1991. Between 1992-1995 he did his post-doc at Northwestern University - USA, in the lab of Prof. Tobin J. Marks. In 1996 he joined the institute of chemistry at the Hebrew University of Jerusalem, Israel. Since 2006 he is a Professor of Chemistry at the Hebrew University. Since 2020 he is the head of the Institute of Chemistry.His major research interests (https://yitzchaik.huji.ac.il/) are biosensors and surface chemistry; he developed developed a modular method to link molecular transducers to various surfaces achieving highly selective and sensitive biosensing devices detecting ions, neurotransmitters, biomolecules, and neuronal activity. More specifically, biosensors for enzymatic activities including kinases and neuraminidases are screened for early diagnosis of lung cancer and autoimmune diseases. Prof. Yitzchaik won the outstanding young scientist prize from the Israeli Chemical Society, the Richard-Willstätteraward from the German Chemical Society, the Applied Materials Research Excellence Prize from the Israel Vacuum Society, the Kaye Innovation award at the Hebrew University, The Braun-Roger-Siegel prize by the Israel Science Foundation,The John van Geuns award by the University of Amsterdam. Currently,he holds the Binjamin H. Birstein Chair in Chemistry.He published more than 140 papers in peer-reviewed journals and holds about 20 patents mostly in the field of biomedical sensors.

Prof Ramesh Gupta is formerPro vice chancellor of Nagaland Central university and Vice Chancellor Radha Govind University,Jharkhand India, had obtained PhD as the age of 23 yearsHe received his Bachelor of Science in Biochemical Science, and Master of Science in organic chemistry, and Doctorate in Chemistry at Lucknow University India, on Drug Development.Dr. Ramesh Gupta is a Medicinal & Bioorganic Chemist andhas worked for several years as visiting professor/Scientist in various Medical schools; Louis pasture University France, University of Arizona USA, Osaka University& Nagoya University Japan, Kyung Hee University, Korea advance institute of science and technology (KAIST) Korea, Ben-Gurion University Israel, Linkoping University Sweden, University of Mons Belgium, University of Western Australia, Sydney ,University of Bergen ,Norway and some others.Prof Guptas’ research focuses on the Natural & Synthetic Drug Development, role of sulfur amino acids in health care, functional food, nutraceuticals and environmental Biotechnology &gender issues.

Semenov Institute of Chemical Physics (Russian Academy of Sciences, Moscow), Department of Chemical and Biological Processes Dynamics [FRC CP RAS, CHEMBIO Dept.], Moscow, Kosygina str. 4 Oleg V. Gradov is the Senior Researcher at the Semenov Institute of Chemical Physics (Russian Academy of Sciences, Moscow), working in the Department of Chemical and Biological Processes Dynamics (CHEMBIO). He is the author of ≈ 200 journal papers. His recent grants include: “Development of the novel physical methods for complex biomedical diagnostics based on position-sensitive mapping with the angular resolution at the tissue and cellular levels using analytical labs-on-a-chip” (RFBR 16-32-00914) and “Lab-on-a-chip development for personalized diagnostics” (FASIE 0019125), "Ferroelectric polymers for biomedical engineering" (RFBR 20-12-50344). He is also an ambassador of “ASAPBio”* (Accelerating Science and Publication in Biology, based in Cambridge, USA). Profiles:  https://www.researchgate.net/profile/Oleg-Gradov  https://www.lens.org/lens/profile/475632185/scholar#  https://istina.msu.ru/profile/gradov/  https://www.linkedin.com/in/oleg-v-gradov-67b368199/  https://www.xing.com/profile/Oleg_Gradov/cv  https://www.facebook.com/o.v.gradov/

Prof. Hanna Romanowicz, During the years 2003-2005, I participated in a training session, organised at the International Centre of Inherited Cancers in Szczecin, supervised by Prof. Jan Lubiński. In the course of the training, I learned in detail the organisation of Outpatient Oncological Genetic Clinics, carried out by a team of Prof. Jam Lubiński. That training helped me organise and open the Outpatient Oncological Genetic Clinic at the Institute-Polish Mother’s Memorial Hospital in Lodz, which I then conductedduring the years 2004-2007 and which was met with great interest and appreciation of patients and physicians. On 4/5 December 2015, I participated in an educational meeting: “Learning of tumour biology as the basis for optimisation of diagnostic-therapeutic management”, held in Warsaw. As a pathologist, I was particularly interested in the aspect of HER2 receptor status. In cases with a borderline status of the HER2 receptor, an evaluation by hybridisation in situ is recommended (e.g., FISH, CISH). I implemented the CISH method at the Department of Clinical Pathomorphology of theInstitute-Polish Mother’s Memorial Hospital, therefore, the above-mentioned meeting was a valuable exchange of experiences with other centres, regarding HER2 evaluation.On 8th June 2016, I participated in the conference: “Biobanks: a challenge in the times of Big Data” in Warsaw. It was an international conference, dedicated to the issue of biobanks as an innovative tool for biomedicine development. My participation in that conference extended my knowledge of the legal regulations and recommendation, concerning the use of data by biobanks. A summary of the scientific output Impact Factor – 130 The Hirsch Index - 19

Prof. Beata Smolarz, Genetics and Radiobiology at the Department of Biology and Environment Protection of the University of Lodz. 2015 - the award of the post-doctoral degree in medical sciences - in the field of medicine 17th June 2015 - the post-doctoral degree in medical sciences in the field of medicine 2020 – the position of Professor of the Polish Mother's Memorial Hospital - Research Institute in Lodz. 2021 - professor Training session 2003-2005, training session, organised at the International Centre of Inherited Cancers in Szczecin, Poland. 2010, training, organised at the Department of Molecular Pathology, the Maria Sklodowska-Curie Institute - Oncology Centre in Warsaw. The training concentrated on mastering the FISH technique, particularly useful in the diagnostics of patients with breast cancer. 2013, training session, organised by the StatSoft Polska, and devoted to: “The application of data mining statistics in scientific research”. 2015, training session: Diagnostic Immunohistochemistry for Pathologists, held in Krakow, 12-13 October 2015. 2015, training at the Department of Clinical Pathomorphology, Polish Mother’s Memorial Hospital - Research Institute in Lodz, which concerned mastering the CISH (chromogenic in-situ hybridisation) technique, especially useful in the diagnostics of patients with breast cancer. 2017, application training in virusological tests on the cobas 4800 system. In the area of my scientific interests, there are studies of genes and their polymorphisms, which may participate in the occurrence of human diseases, such as cancer (breast, ovarian or endometrial), endometriosis and neurological diseases (epilepsy). A summary of the scientific output Impact Factor – 120 The Hirsch Index - 19

Professor 20.01.2023 Dr. Naeem Hasan Khan Faculty of Pharmacy, AIMST University, Ph.D. Doctor of Pharmaceutical Sciences in the discipline of “ Pharmaceutical Chemistry ” from Katholieke Universiteit Leuven (KUL), Leuven, Belgium in Feb., 1988 in the grade of “GREAT DISTINCTION” (the second highest academic grade awarded by the Belgian Universities). M. Pharmacy in the discipline of “Pharmacology” from the University of Punjab, Lahore, Pakistan, in September 1970. B. Pharmacy University of the Punjab, Lahore, Pakistan, in Sept., 1967. F. Sc. Higher Secondary School Certificate examination in the subjects of Pre-Medical group from Govt. College, Lahore, Pakistan, in 1964. Matriculation Secondary School Certificate examination (matriculation) in the subjects of Science group from Govt. Pilot High School, Wahdat Colony, Lahore, Pakistan, in 1962.

Mohammed B Alshammari was born in Saudi Arabia in 1987. He received his B.SC. and M. Sc. degrees in Chemistry from King Saud University, Riyadh, KSA in 2007 under supervision of professor Abdullah almajed and professor Hassan Alhazmi. He Worked in Chemistry department in KSU for 9 years as researcher. He received his Ph.D. degree from Cardiff University, UK, in 2013 under supervision of Professor Keith Smith. His research focused in using of organometallic intermediates in organic synthesis. In 2013, He worked as assistant professor in prince Sattam bin Abdulaziz university and promoted to associate professor in 2019. He has published more than 70 International per-reviewed journal publications and 45 conference proceedings in the area of Organic Chemistry and Chemistry. Supervised 2 M.Sc. students. PI of 3 grants from the University, and 1 grant from the SABIC in collaboration with PSAU. His research interest in the areas of organic synthesis of organic compounds and polymers by difrent methadolgy such as lithiation reaction, Matteson homologation and others. In addition, He published number of papers about the biological activite for synthesied compounds.

Dr. Jinwei Zhang is a Principal Investigator at the University of Exeter Medical School, UK. His laboratory studies ion channels, transporters, and signalling pathways that associated with human diseases, for examples, stroke that regulated by WNK-SPAK/OSR1-KCC2/NKCC1, hypertension that regulated by WNK-SPAK/OSR1-NCC, and concern with elucidating and targeting ion transporters, kinases, protein-protein interactions using genetic mouse models, small molecules, CRISPR/Cas9 gene-editing technologies, and electrophysiology to aid discovery and validation of new potential drug targets. He is internationally recognized for his expertise in cellular chloride homeostasis and cell volume regulation and drug discovery. He has published more than 70 articles in journals including Nature Medicine, Cell Metabolism, Neuron, Nature Communications, EMBO molecular medicine, Science Signalling, Human Molecular Genetics etc. and has achieved more than 2320 citations

Dr. Célia Cabral has a multidisciplinary scientific path and a publication track record on medicinal plants, natural drug leads, phytochemistry, non-communicable diseases and plant-based health solutions.Her current research interests focus on compilation of knowledge about medicinal plants and practices and validation of the medicinal plant uses from Europe, Africa, South America and Asia. She also has vast experience in field work (Portugal and África), herbarium collection, preparation and identification (with an extensive network with reference Herbaria across the World). In summary, her main research objectives has been the pytochemicals identification from natural matrices, especially medicinal plants, identifying natural drug leads and understanding how bioactive molecules, with proven safety and efficacy, target intracellular organelles as mitochondria in noncommunicable diseases such as cardiovascular diseases, non-alcoholic fatty liver disease, cancer, chronic respiratory diseases, diabetes and mental health conditions, that are the leading cause of mortality in the world.

Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined the research group of Professor Xinyong Liu as a Lecturer (2010−2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by JSPS (Japan Society for the Promotion of Science) in the Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel anti-viral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches.

Dr. Roche‐Lima earned his PhD in Computer Sciences from the University of Manitoba, Canada. He has a broad background applying computer science to complex biological data. He joined the Medical Science Campus, University of Puerto Rico (MSC, UPR), where he worksas an Assistant Professor teaching topics such as data science, bioinformatics and biomedical informatics. His research areas are focused on the application of artificial intelligence and machine learning methods for prediction, analysis and interpretation of biomedical data.He is also the Director of the Integrated Informatics Service core (IIS) and Coordinator of the Research Infrastructure core (RIC) of the Center for Collaborative Research in Health Disparities, which is a federal funded center for minority institutions at MSC, UPR. The goals of these coresare to provide one point of contact to assist researchers with the general aspects of biomedical informatics (i.e. bioinformatics, health informatics and operational informatics) and other related areas (e.g. genomics and proteomics) as they apply to the biomedical science research.Dr. Roche-Lima most recent papers describe using novel supervised learning algorithms for the implementation of informatics applications to sience